Foghorn Therapeutics INC 10-Q quarterly reports

Foghorn Therapeutics reports a substantial increase in collaboration revenue for Q2 2026, driven by a catch-up adjustment, while operating expenses decrease, though net losses persist.

Foghorn Therapeutics reports Q1 2026 results with increased cash reserves, reduced operating expenses, and ongoing development in its oncology pipeline.

Foghorn Therapeutics Inc. reported a reduced net loss for the nine months ended September 30, 2025, driven by decreased operating expenses and continued progress in its collaboration with Eli Lilly and Company.

Foghorn Therapeutics Inc. reported a reduced net loss and lower operating expenses for the first half of 2025, driven by strategic program adjustments and continued collaboration with Eli Lilly and Company.

Foghorn Therapeutics' Q1 2025 shows increased collaboration revenue driven by progress in the Lilly partnership, despite ongoing operating losses.

Foghorn Therapeutics reported a net loss of $19.1 million for the third quarter of 2024, with collaboration revenue decreasing due to the termination of the Merck agreement, offset by increased revenue from the Lilly collaboration.

Foghorn Therapeutics reported its second quarter 2024 financial results, highlighting a recent capital raise and ongoing clinical development programs.

Foghorn Therapeutics reported a net loss of $25.0 million for the first quarter of 2024, while continuing to advance its clinical and preclinical programs.